<DOC>
	<DOC>NCT01121588</DOC>
	<brief_summary>This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.</brief_summary>
	<brief_title>An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>histologically or cytologically proven diagnosis of malignancy other than NSCLC positive for translocation or inversion event involving the ALK gene locus positive for ALK amplification events positive for ALK activating point mutations mutations of amplifications involving the cMet gene but not the ALK gene concurrent treatment on another therapeutic clinical trial prior therapy specifically directed against ALK</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>neoplasm malignant</keyword>
	<keyword>lymphoma</keyword>
	<keyword>neuroblastoma</keyword>
	<keyword>Crizotinib</keyword>
	<keyword>anaplastic lymphoma kinase</keyword>
	<keyword>ALK</keyword>
</DOC>